chemotherapy-induced nausea and vomiting
Conditions
Interventions
CINV group:ondansetron
Sponsors
Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 years old; (2) The patient received ondansetron between January 1, 2021 and December 31, 2022; (3) Malignant tumor was confirmed by histopathology or cytology, regardless of tumor type, TNM stage and previous chemotherapy.
Exclusion criteria
Exclusion criteria: (1) Patients with nausea and vomiting and other symptoms 1 week before enrollment; (2) Patients allergic to 5-HT3 receptor antagonists, dexamethasone and NK-1 receptor antagonists; (3) patients who are taking opioids; (4) suffering from central nervous system disease or mental system disease; (5) Patients with active infection or severe complications; (6) Pregnant or lactating population.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response rate;complete control rate;overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of nausea and vomiting in different CINV types;Nausea and vomiting grading; | — |
Countries
China
Contacts
Public ContactJianjun Zhang
Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed